News Coverage from ESC 2024: Vutrisiran Reduces Cardiovascular Risk, Improves Quality of Life in ATTR-CM
The HELIOS-B trial has returned promising results, indicating use of vutrisiran (Amvuttra), a novel RNA interference therapy, could provide significant benefit on both outcomes and quality of life for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Presented at the European Society of Cardiology (ESC) Congress 2024, results indicate use of vutrisiran was associated with reduced all-cause mortality and recurrent cardiovascular events as well as benefits in multiple markers of disease progression, with these effects statistically significant regardless of use as monotherapy or with background tafamidis (Vyndamax).
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
Source: MDMag
